AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3754572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with better performance status, less than three sites of metastases, and without visceral or nodal metastases
Number of subjects: 1168
Study 29766325 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Group (MIG)
Number of subjects: 83
Study 29766325 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intervention Group (CIG)
Number of subjects: 83
Study 27234605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber dam
Number of subjects: 52
Study 27234605 — intervention group
Group type: COMPARATOR
Intervention: No rubber dam
Number of subjects: 52
Study 25156780 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% BCAA
Number of subjects: 0
Study 25156780 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study 25156780 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation in patients
Number of subjects: 0
Study 22846159 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine (titrated up by 5 mg week⁻¹ to 20 mg)
Number of subjects: 29
Study 22846159 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study 21226877 — intervention group
Group type: EXPERIMENTAL
Intervention: Yomogi AGEs Clearing (YAC) extract
Number of subjects: 91
Study 21226877 — intervention group
Group type: COMPARATOR
Intervention: Placebo product without an anti-aging substance
Number of subjects: 91
Study 18657175 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 206
Study 18657175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 16485750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipschitz exponent (LE) method
Number of subjects: 0
Study 16485750 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscale wavelet maximum (ISWM) method
Number of subjects: 0
Study 16485750 — intervention group
Group type: COMPARATOR
Intervention: Turns Analysis (TA) method
Number of subjects: 0
Study 16485750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of the mean LE value to the number of singular points
Number of subjects: 0
Study 15370682 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 10
Study 15370682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11535316 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine, administered orally with childhood vaccines at 2, 4, and 6 months of age
Number of subjects: 20
Study 11535316 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine
Number of subjects: 20
Study 11535316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9692077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent monofluorophosphate 114 mg/day plus continuous calcium supplementation (950-1000 mg/day)
Number of subjects: 64
Study 9692077 — intervention group
Group type: COMPARATOR
Intervention: Continuous calcium (1000 mg/day) alone
Number of subjects: 64
Study 9692077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent monofluorophosphate plus calcium
Number of subjects: 64
Study 9692077 — intervention group
Group type: COMPARATOR
Intervention: Continuous calcium alone
Number of subjects: 64
Study 7848337 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophyllard (test preparation)
Number of subjects: 24
Study 7848337 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 24
Study 2525943 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg, twice daily)
Number of subjects: 30
Study 2525943 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg, twice daily)
Number of subjects: 30
Study 31612201 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of serum retinol
Number of subjects: 29104
Study 30097133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) treatment and clinical monitoring
Number of subjects: 60
Study 30097133 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring only
Number of subjects: 60
Study 26058477 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 51
Study 26058477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 24042479 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration
Number of subjects: 0
Study 24042479 — intervention group
Group type: COMPARATOR
Intervention: No placebo
Number of subjects: 0
Study 23425731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube thoracostomy
Number of subjects: 90
Study 23425731 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 90
Study 20610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Street children experiencing harassment or abuse
Number of subjects: 857
Study 20610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use among street children
Number of subjects: 857
Study 20610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity among older adolescents (15-17 years)
Number of subjects: 857
Study 20610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sexual partners among sexually active adolescents (15-17 years)
Number of subjects: 857
Study 20610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use among sexually active adolescents (15-17 years)
Number of subjects: 857
Study 20610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse among girls
Number of subjects: 857
Study 20610947 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap with high-risk populations for HIV
Number of subjects: 857
Study 17468035 — intervention group
Group type: EXPERIMENTAL
Intervention: Submental approach
Number of subjects: 20
Study 17468035 — intervention group
Group type: COMPARATOR
Intervention: Submandibular approach
Number of subjects: 20
Study 16801296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine spray (active)
Number of subjects: 115
Study 16801296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 115
Study 16801296 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation (12‐hr deprived)
Number of subjects: 115
Study 16801296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondeprived
Number of subjects: 115
Study 14653293 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Flow with manufacturer's dentin adhesive (Single Bond)
Number of subjects: 48
Study 14653293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Flow with manufacturer's dentin adhesive (Prime & Bond NT)
Number of subjects: 48
Study 14653293 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Flow with manufacturer's dentin adhesive (Admira Bond)
Number of subjects: 48
Study 14653293 — intervention group
Group type: COMPARATOR
Intervention: Filtek Flow with different brand dentin adhesive (Gluma Comfort Bond)
Number of subjects: 48
Study 14653293 — intervention group
Group type: COMPARATOR
Intervention: Dyract Flow with different brand dentin adhesive (Gluma Comfort Bond)
Number of subjects: 48
Study 14653293 — intervention group
Group type: COMPARATOR
Intervention: Admira Flow with different brand dentin adhesive (Gluma Comfort Bond)
Number of subjects: 48
Study 11037993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite grafts
Number of subjects: 12
Study 11037993 — intervention group
Group type: COMPARATOR
Intervention: Iliac bone autografts
Number of subjects: 12
Study 11037993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HA grafts and autografts)
Number of subjects: 12
Study 8831304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 21
Study 1466325 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine-SR 45 mg twice daily
Number of subjects: 218
Study 1466325 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine-SR 60 mg twice daily
Number of subjects: 218
Study 1466325 — intervention group
Group type: COMPARATOR
Intervention: verapamil-SR 240 mg once daily
Number of subjects: 218
Study 3970798 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate-neostigmine mixture
Number of subjects: 50
Study 3970798 — intervention group
Group type: COMPARATOR
Intervention: Atropine-neostigmine mixture
Number of subjects: 50
Study 30963443 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarette aerosol with nicotine
Number of subjects: 17
Study 30963443 — intervention group
Group type: COMPARATOR
Intervention: e-cigarette aerosol without nicotine
Number of subjects: 17
Study 29538220 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine warm compress (CMWC)
Number of subjects: 62
Study 29538220 — intervention group
Group type: COMPARATOR
Intervention: WHO 3-step analgesic ladder treatment
Number of subjects: 62
Study 30640989 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional care plus acupoint massage (Zusanli (ST36), Shangjuxu (ST37), Liangqiu (ST34), Yinshi (ST33), Futo (ST32))
Number of subjects: 106
Study 30640989 — intervention group
Group type: COMPARATOR
Intervention: Conventional care plus intermittent limb pressure treatment
Number of subjects: 106
Study 30640989 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (acupoint massage)
Number of subjects: 106
Study 30640989 — intervention group
Group type: COMPARATOR
Intervention: Control group (intermittent limb pressure treatment)
Number of subjects: 106
Study 30640989 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 106
Study 24668714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) added to 30 ml 0.25% levobupivacaine
Number of subjects: 42
Study 24668714 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine (30 ml 0.25%) with 2 ml 0.9% NaCl
Number of subjects: 42
Study 23415776 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (fortified cefazolin sodium 5% and tobramycin sulfate 1.3%)
Number of subjects: 224
Study 23415776 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy (moxifloxacin 0.5%)
Number of subjects: 224
Study 20856180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP)
Number of subjects: 50
Study 18212034 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week cardiac rehabilitation programme (16 cycle ergometry sessions and 2 stress-management classes)
Number of subjects: 48
Study 18212034 — intervention group
Group type: COMPARATOR
Intervention: Usual care (excluding aerobic exercise)
Number of subjects: 48
Study 15818702 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg etoricoxib
Number of subjects: 387
Study 15818702 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib
Number of subjects: 387
Study 15818702 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 1000 mg
Number of subjects: 387
Study 12535740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 90
Study 12535740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12535740 — intervention group
Group type: EXPERIMENTAL
Intervention: DM group
Number of subjects: 90
Study 12535740 — intervention group
Group type: EXPERIMENTAL
Intervention: HC group
Number of subjects: 90
Study 15613223 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg tablet during migraine (n=18)
Number of subjects: 21
Study 15613223 — intervention group
Group type: COMPARATOR
Intervention: Rizatriptan 5 mg tablet in migraine-free state (n=21)
Number of subjects: 21
Study 15613223 — intervention group
Group type: COMPARATOR
Intervention: Placebo during migraine (n=3)
Number of subjects: 21
Study 15613223 — intervention group
Group type: COMPARATOR
Intervention: Placebo in migraine-free state (n=21)
Number of subjects: 21
Study 8877276 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute metformin administration (850 mg single dose)
Number of subjects: 12
Study 8877276 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic metformin treatment (850 mg twice a day for a month)
Number of subjects: 12
Study 8877276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1792618 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (30‐60 mg/day)
Number of subjects: 46
Study 1792618 — intervention group
Group type: EXPERIMENTAL
Intervention: aldizem (180‐270 mg/day)
Number of subjects: 46
Study 3011583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aluminum-magnesium antacid regimen (Link one tablet q.i.d.)
Number of subjects: 86
Study 3011583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 3011583 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 86
Study 3011583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fiber diet
Number of subjects: 86
Study 31728609 — intervention group
Group type: EXPERIMENTAL
Intervention: GEWF solution
Number of subjects: 0
Study 31728609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnoy solution
Number of subjects: 0
Study 31728609 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 0
Study 30125815 — intervention group
Group type: EXPERIMENTAL
Intervention: Video animations with different frames conveying messages about recycled water safety
Number of subjects: 689
Study 30125815 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety message framed in terms of the selection of water treatment technology to remove contaminants
Number of subjects: 689
Study 30125815 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety message framed in terms of non-potable water risks relative to other everyday risks
Number of subjects: 689
Study 27912960 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 31
Study 27912960 — intervention group
Group type: COMPARATOR
Intervention: No music intervention
Number of subjects: 31
Study 24618485 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous polyethylene implant with mucus membrane graft (MMG)
Number of subjects: 24
Study 24618485 — intervention group
Group type: COMPARATOR
Intervention: Dermis fat graft (DFG)
Number of subjects: 24
Study 22978720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke particulate matter (PM) exposure in vitro
Number of subjects: 5
Study 22978720 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking cessation for 5 days
Number of subjects: 5
Study 20545210 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianliening Tang (QLNT), daily potion, two times a day for 8 weeks
Number of subjects: 0
Study 20545210 — intervention group
Group type: COMPARATOR
Intervention: Qianliekang, three times a day, three pills each time for 8 weeks
Number of subjects: 0
Study 20545210 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy group (group C)
Number of subjects: 0
Study 22791754 — intervention group
Group type: COMPARATOR
Intervention: hCG 0 IU/day (D0)
Number of subjects: 62
Study 22791754 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 50 IU/day (D50)
Number of subjects: 62
Study 22791754 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 100 IU/day (D100)
Number of subjects: 62
Study 22791754 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 150 IU/day (D150)
Number of subjects: 62
Study 15745836 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 15745836 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 12752555 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge
Number of subjects: 23
Study 12752555 — intervention group
Group type: COMPARATOR
Intervention: Saline lavage
Number of subjects: 23
Study 12752555 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge in COPD patients with nasal symptoms
Number of subjects: 23
Study 9467046 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microgram/kg recombinant human interleukin-4
Number of subjects: 63
Study 9467046 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microgram/kg recombinant human interleukin-4
Number of subjects: 63
Study 7699303 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually supervised physical activity program (2 sessions of 90 minutes each for 10 weeks)
Number of subjects: 45
Study 7699303 — intervention group
Group type: COMPARATOR
Intervention: Equal individualized attention through extra academic instruction (Control group)
Number of subjects: 45
Study 2496671 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective isolation (private room, hat, mask, sterile gown, handwashing)
Number of subjects: 60
Study 2496671 — intervention group
Group type: COMPARATOR
Intervention: No isolation (crowded, open intensive care unit)
Number of subjects: 60
Study 782463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with naproxen and aspirin
Number of subjects: 36
Study 782463 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 36
Study 782463 — intervention group
Group type: COMPARATOR
Intervention: Naproxen and placebo
Number of subjects: 36
Study 30690848 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-level (IL) FPD
Number of subjects: 50
Study 30690848 — intervention group
Group type: COMPARATOR
Intervention: Abutment-level (AL) FPD
Number of subjects: 50
Study 30690848 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IL and AL FPD
Number of subjects: 50
Study 28765681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 38
Study 28765681 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (Control)
Number of subjects: 38
Study 25395191 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 20
Study 25395191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23782591 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (ChEI) including donepezil, rivastigmine, and galantamine
Number of subjects: 0
Study 23782591 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Aging Brain Care Monitor and Neuropsychiatric Inventory
Number of subjects: 0
Study 23782591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic signatures evaluation
Number of subjects: 0
Study 22174580 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB/CCB/HCTZ (valsartan/amlodipine 160/5 mg + HCTZ 25 mg)
Number of subjects: 84
Study 18490561 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 100
Study 18490561 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 100
Study 16543688 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (benazepril 1.25 to 5 mg daily or trandolapril 0.5 to 4 mg daily)
Number of subjects: 68
Study 16543688 — intervention group
Group type: COMPARATOR
Intervention: ARB (candesartan 2 to 8 mg daily or losartan 25 to 100 mg daily)
Number of subjects: 68
Study 16543688 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor
Number of subjects: 68
Study 16543688 — intervention group
Group type: COMPARATOR
Intervention: ARB
Number of subjects: 68
Study 14633812 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day)
Number of subjects: 1031
Study 14633812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/day)
Number of subjects: 1031
Study 14633812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin or vitamin E)
Number of subjects: 1031
Study 10990044 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1%/gentamicin 0.3% drops 4X/day until day 12-14 and diclofenac sodium 0.1% 3X/day until day 28
Number of subjects: 87
Study 10990044 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone phosphate 0.1% drops 4X/day until postoperative day 12-14 and 3X/day until day 28 and gentamicin 0.3% drops 4X/day until day 12-14
Number of subjects: 87
Study 8884623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin 50 mg
Number of subjects: 20
Study 8884623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1372124 — intervention group
Group type: COMPARATOR
Intervention: Iloprost (ZK 36 374) administered via infusion up to 12 ng kg-1 min-1 before and during ECC.
Number of subjects: 30
Study 3979238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg qid
Number of subjects: 6
Study 3979238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 6
Study 3979238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30440010 — intervention group
Group type: EXPERIMENTAL
Intervention: Angola performance
Number of subjects: 11
Study 30440010 — intervention group
Group type: EXPERIMENTAL
Intervention: Benguela performance
Number of subjects: 11
Study 30440010 — intervention group
Group type: EXPERIMENTAL
Intervention: São Bento performance
Number of subjects: 11
Study 27199278 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy performed concurrently with oocyte retrieval (n = 150)
Number of subjects: 300
Study 27199278 — intervention group
Group type: COMPARATOR
Intervention: ICSI freeze-all cycles without hysteroscopy (control group, n = 150)
Number of subjects: 300
Study 24858963 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.6% carbohydrate-containing drink (10 mL kg(‐1) the evening before surgery and two hours before anaesthesia)
Number of subjects: 20
Study 24858963 — intervention group
Group type: COMPARATOR
Intervention: Fasting (Control Group 2)
Number of subjects: 20
Study 22361576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Fatigue Inventory (MFI)
Number of subjects: 153
Study 20120622 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sleep disturbance prior to injury
Number of subjects: 1033
Study 20120622 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sleep disturbance prior to injury who had never experienced a prior disorder (n = 324)
Number of subjects: 1033
Study 20120622 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without sleep disturbance prior to injury)
Number of subjects: 1033
Study 18279765 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor) as initial adjuvant therapy
Number of subjects: 0
Study 15962646 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a pre‐recorded explanation and music
Number of subjects: 110